Advanced Solid Cancer Clinical Trials

15 recruitingLast updated: June 17, 2026

There are 15 actively recruiting advanced solid cancer clinical trials across 9 countries. Studies span Phase 1, Phase 2, Early Phase 1, Phase 3. Top locations include New York, New York, United States, Shanghai, Shanghai Municipality, China, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Advanced Solid Cancer Trials at a Glance

15 actively recruiting trials for advanced solid cancer are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in New York, Shanghai, and Barcelona. Lead sponsors running advanced solid cancer studies include Jiangsu Simcere Pharmaceutical Co., Ltd., Arvinas Inc., and Aptabio Therapeutics, Inc..

Browse advanced solid cancer trials by phase

Treatments under study

About Advanced Solid Cancer Clinical Trials

Looking for clinical trials for Advanced Solid Cancer? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Solid Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Solid Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 1

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

Metastatic Solid TumorsAdvanced Solid CancersAdvanced Malignancy
Adcytherix SAS290 enrolled9 locationsNCT07238075
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

Ovarian CancerEndometrial CancerBreast Cancer (Locally Advanced or Metastatic)+2 more
Shenzhen Ionova Life Sciences Co., Ltd.201 enrolled1 locationNCT07612891
Recruiting
Phase 1

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

Advanced Solid CancerMetastatic Solid Cancer
Boehringer Ingelheim60 enrolled9 locationsNCT07607678
Recruiting
Phase 1

SIM0613 in Participants With Advanced Solid Tumors

Advanced Solid Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.294 enrolled1 locationNCT07618260
Recruiting
Phase 1Phase 2

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Advanced Solid Cancers
BioNTech SE245 enrolled10 locationsNCT07186842
Recruiting
Phase 2Phase 3

Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients

Advanced Solid Cancers
Intra-IMMUSG Pte Ltd52 enrolled4 locationsNCT07290088
Recruiting
Early Phase 1

Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers

Advanced Solid Cancers
Hainan Cancer Hospital10 enrolled1 locationNCT07475182
Recruiting
Phase 1Phase 2

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Advanced Solid CancerKRAS G12D Mutation
Arvinas Inc.159 enrolled14 locationsNCT07023731
Recruiting
Phase 1

A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

Advanced Solid Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.232 enrolled6 locationsNCT07265921
Recruiting
Phase 1

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Advanced Solid CancerAdvanced Solid Tumor (Phase 1)
Aptabio Therapeutics, Inc.110 enrolled3 locationsNCT07123415
Recruiting
Phase 1Phase 2

A Study of MHB046C Injection in Patients With Advanced Solid Tumors

Advanced Solid Cancer
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT06985355
Recruiting
Phase 1

Study of SC-102 in Patients With Advanced Solid Tumors

Advanced Solid Cancers
Tianjin ConjuStar Biologics Co., Ltd.120 enrolled1 locationNCT06710158
Recruiting
Phase 1

A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors

Advanced Solid Cancers
Zhejiang Hisun Pharmaceutical Co. Ltd.110 enrolled1 locationNCT07092748
Recruiting
Phase 1

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

Breast CancerOvarian CancerProstate Cancer+4 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd30 enrolled2 locationsNCT06666270
Recruiting
Phase 1

APG-2449 in Patients With Advanced Solid Tumors

Esophageal CancerOvarian CancerNon-small Cell Lung Cancer+2 more
Ascentage Pharma Group Inc.165 enrolled9 locationsNCT03917043